1. AB0420 Secondary Efficacy Outcomes from a Phase 3 Study Support Clinical Equivalence Between BOW015 and Infliximab in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses. (9th June 2015) Authors: Kay, J.; Chopra, A.; Chandrashekara, S.; Olakkengil, D.; Bhojani, K.; Bhatia, G.; Rathi, G.; Thomas, M.; Maroli, S.; Thomson, E.; Lassen, C.; Shneyer, L.; Wyand, M. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 1034 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Discovery of inconsistent generalised coherent rules. (4th May 2021) Authors: Anuradha, R.; Rajkumar, N.; Rathi, G.; Brighty, S. Prince Sahaya Journal: International journal of business intelligence and data mining Issue: Volume 18:Number 4(2021) Page Start: 435 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OP0012 A Phase 3, Randomized, Double-Blind, Active Comparator Study of the Efficacy and Safety of Bow015, A Biosimilar Infliximab, in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses. (10th June 2014) Authors: Kay, J.; Chopra, A.; Chandrashekara, S.; Olakkengil, D.J.; Bhojani, K.S.; Bhatia, G.; Rathi, G.; Thomas, M.; Maroli, S.; Thomson, E.S.; Shneyer, L.; Wyand, M.S. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 64 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗